Home›Dordaviprone›Dordaviprone + Mao Inhibitors

Does Dordaviprone Interact with Mao Inhibitors?

Dordaviprone and Mao Inhibitors have a major drug interaction according to U.S. FDA drug labeling data. Strong CYP3A4 inhibitors increase dordaviprone exposure, which may increase the risk of MODEYSO-related adverse reactions. Avoid concomitant use or reduce MODEYSO dose if unavoidable. The mechanism involves dordaviprone is a cyp3a4 substrate; inhibitors increase its exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Dordaviprone Class
Protease Activator
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Dordaviprone and Mao Inhibitors occurs because dordaviprone is a cyp3a4 substrate; inhibitors increase its exposure. Clinically, this means strong cyp3a4 inhibitors increase dordaviprone exposure, which may increase the risk of modeyso-related adverse reactions. avoid concomitant use or reduce modeyso dose if unavoidable. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Dordaviprone and your doctor is considering prescribing Mao Inhibitors (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Dordaviprone(Modeyso)+💊 Mao Inhibitors

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Protease Activator
Drug B class
—
Source
NLP:dordaviprone

What this means in plain English

Strong CYP3A4 inhibitors increase dordaviprone exposure, which may increase the risk of MODEYSO-related adverse reactions. Avoid concomitant use or reduce MODEYSO dose if unavoidable.

About Dordaviprone and Mao Inhibitors

Dordaviprone is a Protease Activator. Dordaviprone is also sold under the brand name Modeyso. Dordaviprone is taken by mouth.

What the FDA label says

"Dordaviprone is a CYP3A4 substrate; inhibitors increase its exposure"

📖 Source: NLP:dordaviprone

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Dordaviprone and Mao Inhibitors against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.